ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325 - Takeaways - MDSpire

ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

Share

  • 1

    The Pumitamig + DB-1305/BNT325 trial results were presented at the 2026 ESMO Breast Cancer Congress.

  • 2

    Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD, discussed the trial findings.

  • 3

    The trial investigated the combination of Pumitamig with DB-1305/BNT325.

  • 4

    Details regarding the efficacy and safety of the treatment were highlighted during the presentation.

  • 5

    The discussion focused on the implications of the trial results for breast cancer treatment.

Original Source(s)

ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325

  • June 26, 2026

Related Content

Quercetagetin-rich flavonoids from marigold induce apoptosis inhibit metastasis of non-small cell lung cancer via the p53/p21 signaling pathway

The mechanism of action, clinical significance, and research progress of tumor antigen-specific T cells in the treatment of HCC

Effectiveness of a Home-Based and Group-Based Tele-Exercise Program for Breast Cancer Survivors: Pilot Randomized Controlled Trial